Document:

Execution
Copy

 

SHARE
EXCHANGE AGREEMENT

 

THIS
AGREEMENT dated as of the 24th day of July, 2017 (the “Effective Date”).

 

A
M O N G :

BRIACELL
THERAPEUTICS CORP., a corporation existing under the laws of the State of Delaware

 

(hereinafter
called the “Acquiror”)

 

OF
THE FIRST PART

 

-
and -

 

BRIACELL
THERAPEUTICS CORP., a corporation existing under the laws of the Province of British Columbia

(hereinafter
called “BriaCell”)

 

OF
THE SECOND PART

 

-
and -

 

SAPIENTIA
PHARMACEUTICALS, INC., a corporation existing under the laws of the State of Delaware

(hereinafter
called “Sapientia”)

 

OF
THE THIRD PART

 

-
and -

 

THE
INDIVIDUALS SET OUT IN EXHIBIT “A” HERETO

(hereinafter
collectively called the “Sapientia Shareholders”)

 

OF
THE FOURTH PART

RECITALS

 

	A.	BriaCell
    is a publicly traded biotechnology company listed on the TSX Venture Exchange (“Exchange”).
	 	 
	B.	The
    Acquiror is a wholly-owned subsidiary of BriaCell.
	 	 
	C.	Sapientia
    is a privately held biotechnology company organized under the laws of the State of Delaware.

 

    	 	 	 

    	 	-2-	 

    

 

	D.	The
    Sapientia Shareholders are collectively the legal and beneficial owners of all of the issued and outstanding common shares
    in the capital of Sapientia (the “Sapientia Shares”).
	 	 
	E.	The
    boards of directors of the Acquiror, BriaCell and Sapientia have determined that it is in the best interests of their respective
    corporations and their respective shareholders that the corporations effect the transactions contemplated by this Agreement
    subject to and on the terms and conditions set forth herein.
	 	 
	F.	The
    Shareholders desire to sell the Sapientia Shares and the Acquiror desires to acquire such Sapientia Shares in consideration
    for the issuance to the Sapientia Shareholders pro rata an aggregate of 2,500,000 common shares in the capital of BriaCell
    (the “BriaCell Payment Shares”), all as more particularly described herein and upon the terms and conditions
    hereinafter set forth.
	 	 
	G.	BriaCell
    and Sapientia intend that the transfer of the Sapientia Shares and BriaCell Payment Shares be accomplished on a tax-free basis
    pursuant to the provisions of Section 368(a)(1)(B) of the Internal Revenue Code of 1986.

 

NOW
THEREFORE THIS AGREEMENT WITNESSETH THAT in consideration of the mutual promises and covenants contained herein, and other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby covenant and
agree as follows:

 

ARTICLE
1

INTERPRETATION

 

	1.1	Definitions

 

In
this Agreement and in all amendments hereto the following words, whenever used in this Agreement, unless there is something in
the subject matter or context inconsistent therewith, shall have the following meanings:

 

“Affiliates”
shall include the spouses, parents, children and other members of the families of the Shareholders and any Person controlled
by the Shareholders or any one or more of them.

 

“Agreement”
shall mean this Share Exchange Agreement as amended from time to time.

 

“Claims,
Proceedings or Restrictions” shall mean any claims, legal, administrative or other proceedings, suits, investigations,
complaints, notices of violation or similar process, judgments, injunctions, orders, decrees or directives against, relating to
or directly or indirectly affecting (a) Sapientia, its assets, business or its ability to acquire property or conduct business
in any area, or (b) the officers or directors, agents, employees or consultants of Sapientia, which as to all matters described
in (a) or (b) above if determined adversely to any of the above (or if adopted in the case of proposed governmental restriction),
might individually or in the aggregate, either materially adversely affect the condition (financial or otherwise), operations,
business or prospects of Sapientia, or challenge the validity or propriety of the transactions contemplated by the Agreement,
or the ability of the parties to consummate such transactions in accordance with the terms of the Agreement.

 

“Closing
Date” shall mean the date on which the Closing occurs.

 

“BriaCell
Shares” means common shares in the capital of BriaCell.

 

    	 	 	 

    	 	-3-	 

    

 

“Intellectual
Property” shall mean all patents, trademarks, copyrights, industrial designs, software, trade secrets, know-how, concepts,
information and other intellectual and industrial property.

 

“Financial
Statements” shall mean Sapientia’s financial statements including balance sheet as at December 31, 2016 and the
related statements of income, retained earnings and changes in financial position for the period then ended.

 

“License
Agreement” means the License Agreement dated March 16, 2017 by and between Sapientia Pharmaceuticals, Inc. and Faller
& Williams Technology LLC.

 

“material”
or “materially”, as used in connection with events, contingencies, claims or other matters (or a series
of related such matters) expressly relating in the Agreement to any particular asset of Sapientia or the business of Sapientia
as the case may be, shall include such matters as a reasonably prudent investor would consider important (either, individually,
or when considering the collective effect of all such matters) in deciding whether to purchase such assets, the Sapientia Shares,
or the business of Sapientia on the terms provided herein.

 

“Person”
shall mean any individual, sole proprietorship, partnership, joint venture, trust, unincorporated organization, association,
limited liability company, corporation, institution, public benefit corporation, entity or government (whether federal, provincial,
county, city, municipal or otherwise, including, without limitation, any instrumentality, division, agency, body or department
thereof).

 

“Purchase
Price” shall mean the aggregate consideration to be paid to the Sapientia Shareholders pursuant to Section 2.1 (a).

 

“Securities
Laws” means the securities legislation having application, the regulations and rules thereunder and all administrative
policy statements, instruments, blanket orders, notices, directions and rulings issued or adopted by the applicable securities
regulatory authority, all as amended.

 

“Taxes”
means all taxes and other governmental charges of any kind whatsoever including without limitation, all federal, state, municipal
or other governmental imposed income tax, capital tax, capital gains tax, transfer tax, value-added tax, sales tax, social services,
health, payroll and employment taxes, duty, customs, or import duties and any penalty charges or interest in respect of the forgoing.

 

ARTICLE
2

PURCHASE
AND SALE

 

	2.1	Purchase
    and Sale

 

	 	(a)	Subject
    to the terms and conditions of this Agreement, each of the Sapientia Shareholders agrees to sell all of their ownership interest
    in and to the Sapientia Shares, as described in Schedule 2.1(a), to BriaCell free and clear of all encumbrances and the Acquiror
    agrees to purchase all of the Sapientia Shares.
	 	 	 
	 	(b)	As
    consideration for the Sapientia Shares, BriaCell shall issue pro rata to the Sapientia Shareholders an aggregate of
    2,500,000 BriaCell Payment Shares at the Market Price (as such term is defined in the Exchange Corporate Financial Manual)
    of the BriaCell Shares on the Closing Date. The BriaCell Payment Shares will be issued to the Sapientia Shareholders on a
    pro rata basis based on the number of Sapientia Shares owned by each Sapientia Shareholder immediately prior to Closing
    (as defined herein).

 

    	 	 	 

    	 	-4-	 

    

 

ARTICLE
3

REPRESENTATIONS
AND WARRANTIES RELATING TO SAPIENTIA

 

Sapientia
represents and warrants as of the date of this Agreement and again as of the date of Closing Date to BriaCell as follows:

 

	3.1	Organization,
    Power and Qualification

 

Sapientia
is a corporation duly incorporated, organized and validly subsisting under the laws of the State of Delaware, and has all requisite
corporate power and authority to own or hold under lease its properties and assets and to carry on its business as now conducted.
Sapientia is duly qualified to do business and is in good standing in every jurisdiction in which a failure to so qualify could
have a Material adverse effect upon its properties, assets, financial conditions, results of operation or business prospects.
True and complete copies of the Articles of Incorporation, as amended to date, and the by- laws, as amended to date, of Sapientia
have been furnished to BriaCell. Sapientia has taken all actions required by law, its Articles of Incorporation, or otherwise,
to authorize the execution and delivery of this Agreement. Sapientia has full power, authority, and legal right and has taken
all action required by law, its Articles of Incorporation, and otherwise, to consummate the transactions herein contemplated.

 

	3.2	Capitalization

 

The
authorized capitalization of Sapientia consists of an unlimited number of common stock of which 4,106,653 shares are currently
issued and outstanding and 57,000 common stock options with an exercise price of USD$0.01 which will be converted into common
stock on the Closing Date. All issued and outstanding shares are legally issued, fully paid, and non-assessable and not issued
in violation of preemptive or other rights of any person. All of the currently issued and outstanding stock in the capital of
Sapientia are duly authorized, validly issued and outstanding, as fully paid and non- assessable and have not been issued in violation
of any shareholder rights under applicable law, or of the certificate or articles of incorporation or by-laws or the terms of
any agreement to which Sapientia is a party or by which Sapientia is bound. Sapientia has no outstanding subscriptions, options,
warrants, rights or other agreements granting to any person, firm or corporation any interest in or right to acquire from the
Corporation at any time, or upon the happening of any stated event, any shares in the capital of the Corporation, or any interest
therein

 

	3.3	Subsidiary
    Corporations

 

Sapientia
does not have any predecessor corporation(s) or subsidiaries, and does not own, beneficially or of record, any shares of any other
corporations

 

    	 	 	 

    	 	-5-	 

    

 

	3.4	No
    Violation

 

Neither
the execution and delivery of this Agreement, nor the consummation of the transactions contemplated hereby will constitute a violation
of, or be in conflict with, or result in a cancellation of, or constitute a default under, or create (or cause the acceleration
of the maturity of) any debt, obligation or liability affecting, or result in the creation or imposition of any security interest,
lien, or other encumbrance upon any of the assets owned or used by, or any of the capital stock of, Sapientia under:

 

	 	(a)	any
    term or provision of the certificate or articles of incorporation or by-laws of Sapientia;
	 	 	 
	 	(b)	any
    contract, agreement, indenture, lease or other commitment to which Sapientia or the Sapientia Shareholders is or are party
    or by which Sapientia or the Sapientia Shareholders is or are bound;
	 	 	 
	 	(c)	any
    judgment, decree, order, regulation or rule of any court or governmental authority; or
	 	 	 
	 	(d)	any
    statute or law.

 

No
consent of, or notice to, any federal, state, or local authority, or any private person or entity, is required to be obtained
or given by the Sapientia Shareholders or Sapientia in connection with the execution, delivery or performance of this Agreement
or any other agreement or document to be executed, delivered or performed hereunder by the Sapientia Shareholders or Sapientia.

 

	3.5	Financial
    Statements

 

The
Financial Statements (i) have been prepared in accordance with US GAAP and fairly present the financial condition, assets and
liabilities (whether accrued, absolute, contingent or otherwise) of Sapientia as of the respective dates thereof and the results
of operations and changes in financial position of Sapientia for the periods covered thereby; (ii) Sapientia has no liabilities
with respect to the payment of any federal, state, local or other taxes (including any deficiencies, interest or penalties), except
for taxes accrued but not yet due and payable; and (iii) Sapientia has filed all federal, state or local income and/or franchise
tax returns required to be filed by it from inception to the date hereof and each of such income tax returns reflects the taxes
due for the period covered thereby.

 

	3.6	Absence
    of Certain Changes

 

Since
the date of the Financial Statements, there has not been any Material adverse change in the condition (financial or otherwise)
of the properties, assets, liabilities, results of operation or business prospects of Sapientia.

 

	3.7	Liabilities
    and Obligations

 

Other
than the liabilities and obligations of Sapientia owning to or in favour of Faller & Williams Technology LLC pursuant to the
License Agreement, Sapientia will not at Closing have any liabilities or obligations (direct or indirect, contingent or absolute,
matured or unmatured) of any nature whatsoever, whether arising out of contract, tort, statute or otherwise, other than the liabilities
and obligations.

 

    	 	 	 

    	 	-6-	 

    

 

	3.8	Title
    to and Condition of Assets

 

Sapientia
has good and marketable title to all of its properties, inventory, interests in properties, and assets, real and personal, which
are reflected in the Financial Statements (except properties, inventory, interests in properties, and assets sold or otherwise
disposed of since such date in the ordinary course of business), free and clear of all liens, pledges, charges, or encumbrances
except (a) statutory liens or claims not yet delinquent, (b) such imperfections of title and easements as do not and will not
materially detract from or interfere with the present or proposed use of the properties subject thereto or affected thereby or
otherwise materially impair present business operations on such properties. Sapientia owns, free and clear of any liens, claims,
encumbrances or other restrictions or limitations of any nature whatsoever, any and all products it is currently manufacturing,
including the underlying technology and data, and all intellectual property, procedures, techniques, marketing plans, business
plans, methods of management, or other information utilized in connection with Sapientia’s business. No third party has
any right to, and Sapientia has not received any notice of infringement of or conflict with asserted rights of others with respect
to any product, technology, data, trade secrets, know-how, propriety techniques, trademarks, service marks, trade names, or copyrights
which, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would Materially affect
the business, operations, financial condition, income, or business prospects of Sapientia or any material portion of its properties,
assets, or rights.

 

	3.9	Contracts

 

	 	(a)	Except
    as disclosed in Schedule 3.9, there are no contracts, agreements, franchises, license agreements, debt instruments or other
    commitments to which Sapientia is a party or by which it or any of its assets, products, technology, or properties are bound
    other than those incurred in the ordinary course of business which (i) will remain in effect for more than six (6) months
    after the date of this Agreement, and (ii) involves aggregate obligations of at least twenty-five thousand dollars ($25,000);
	 	 	 
	 	(b)	Sapientia
    is not a party to or bound by, and the properties of Sapientia are not subject to any contract, agreement, other commitment
    or instrument; any charter or other corporate restriction; or any judgment, order, writ, injunction, decree, or award which
    materially and adversely affects, the business operations, properties, assets, or financial condition of Sapientia;
	 	 	 
	 	(c)	Except
    as included or described in Schedule 3.9 or reflected in the Financial Statements, Sapientia is not a party to any oral or
    written (i) contract for the employment of any officer or employee which is not terminable on 30 days, or less notice; (ii)
    profit sharing, bonus, deferred compensation, stock option, severance pay, pension benefit or retirement plan; (iii) agreement,
    contract, or indenture relating to the borrowing of money; (iv) guaranty of any obligation, other than one on which Sapientia
    is a primary obligor, for the borrowing of money or otherwise, excluding endorsements made for collection and other guaranties
    of obligations which, in the aggregate do not exceed more than one year or providing for payments in excess of $25,000 in
    the aggregate; (v) agreement with any present or former officer or director of Sapientia; and
	 	 	 
	 	(d)	and
    all such contracts are now in good standing and in full force and effect without amendments thereto and is entitled to all
    benefits thereunder.

 

    	 	 	 

    	 	-7-	 

    

 

	3.10	No
    Default, Violation or Litigation

 

Sapientia
is not in violation of any law, regulation or order of any court or federal, state, municipal or other governmental department,
commission, board, bureau, agency or instrumentality including, without limitation, laws, regulations, orders, restrictions and
compliance schedules applicable to environmental standards and controls, wages and hours, human rights and occupational health
and safety. There are no lawsuits, proceedings, claims or governmental investigations pending or, to the knowledge of the Sapientia
Shareholders, threatened against, or involving, Sapientia or against its property or business. There is no basis known to the
Sapientia Shareholders for any such action which could have a material adverse effect upon the properties, assets, liabilities,
financial condition, results of operations or business prospects of Sapientia or its right to conduct its business as presently
conducted. There are no judgments, consents, decrees, injunctions, or any other judicial or administrative mandates outstanding
against Sapientia.

 

	3.11	Employment,
    Labour and Other Relations

 

Sapientia
is not a party to or is otherwise bound by any contract, agreement or collective bargaining agreement with any labour union or
organization.

 

	3.12	Employee
    Benefits

 

Sapientia
does not have, and never has had, any pension, retirement, savings, disability, medical, dental, health, life (including any individual
life insurance policy to which Sapientia makes premium payments, whether or not Sapientia is the owner, beneficiary or both of
such policy), death benefit, group insurance, profit sharing, deferred compensation, stock option, bonus, incentive, vacation
pay, severance pay, or other employee benefit plan, trust, arrangement, contract, agreement, policy or commitment.

 

	3.13	Patents,
    etc.

 

	 	(a)	Sapientia
    is the sole owner of all rights, title and interest in the Intellectual Property and owns, possesses or has licenses or similar
    rights to utilize all other patents, trademarks, trade names, service marks, franchises, and technology necessary for the
    conduct of its business as presently conducted without any infringement of or conflict with the rights of others. All such
    patents, trademarks, trade names, service marks and franchises, or applications therefore, are disclosed in Schedule 3.13
    and all licenses therefore are disclosed in Schedule 3.13, and Sapientia’s interests therein are similarly disclosed.
	 	 	 
	 	(b)	There
    have never been, and are not currently, any disputes of any kind regarding the Intellectual Property, including, without limitation,
    any disputes regarding infringement, validity or ownership of the intellectual property rights relating to the Intellectual
    Property.
	 	 	 
	 	(c)	No
    person has made any claim or allegation that any of the Intellectual Property or rights relating thereto do not belong to
    Sapientia or that use of the Intellectual Property in any way violate their intellectual property rights, and Sapientia is
    not aware of any claim or potential claim or allegation of this nature or that may impact the ability of BriaCell or its permitted
    assigns to use the Intellectual Property.

 

    	 	 	 

    	 	-8-	 

    

 

	 	(d)	Sapientia
    has the uninterrupted use of the Intellectual Property and to the practice of the methods and inventions as provided for by
    Sapientia.

 

	3.14	Approvals

 

Sapientia
possesses or has applied for all material governmental and other permits, licenses, consents, certificates, orders, authorizations
and approvals (the “Approvals”) to own or hold under lease and operate its property and assets and to carry
on its business as now conducted. Neither the Sapientia Shareholders nor Sapientia has received any notice of proceedings relating
to the revocation or modification of any such Approvals which, singly or in the aggregate, if the subject of an unfavourable ruling
or finding, could materially adversely affect the properties, assets, financial condition, results of operation or business prospects
of Sapientia.

 

	3.15	Transactions
    with Affiliates

 

Sapientia
is not indebted to and has no liabilities or obligations for any amounts or obligations owing to or in favour of the Sapientia
Shareholders or any of their Affiliates.

 

	3.16	Corporate
    Records

 

All
of the minute books and stock record books of Sapientia have been made available to BriaCell and its agents for inspection, are
accurate and correct in all material respects, and contain all of the corporate minutes and stock records of Sapientia from inception
to the date hereof. Such minutes and records for the period from this date to the Closing Date will be made available to BriaCell
on or before Closing. All accounts, books, ledgers, financial and other records of whatsoever kind of Sapientia have been fully,
properly and accurately maintained in all material respects and all transactions of Sapientia that are reflected therein are truly
and accurately reflected in all material respects.

 

	3.17	Confidential
    Information and Employee Intentions

 

To
the best knowledge of the Sapientia Shareholders and Sapientia:

 

	 	(a)	each
    present employee, officer, director, agent or consultant of Sapientia possessing confidential know-how regarding the business
    or assets Sapientia has maintained the confidentiality of said know-how and has not and is not known to intend to use any
    such know-how of Sapientia in a competitive business; and
	 	 	 
	 	(b)	no
    key employee intends to establish or join a business competitive thereto.

 

	3.18	Other
    Material Adverse Information

 

Except
as expressly set forth in this Agreement and the Schedules or in the Financial Statements, Sapientia has no knowledge of any facts
which will or may reasonably be expected to have any Material adverse effect on the value of the business or goodwill of Sapientia,
or upon its prospects or earning power.

 

    	 	 	 

    	 	-9-	 

    

 

	3.19	Disclosure

 

No
representation or warranty of Sapientia made hereunder or in the Schedules or in any certificate, statement or other document
delivered by or on behalf of Sapientia contains any untrue statement of a material fact or omits to state a material fact necessary
in order to make the statements contained herein or therein not misleading. Copies of all documents referred to herein or in the
Schedules have been delivered or made available to BriaCell, are true, correct and complete copies thereof, and include all amendments,
supplements or modifications thereto or waivers thereunder.

 

ARTICLE
4

ADDITIONAL
REPRESENTATIONS AND WARRANTIES OF THE SAPIENTIA 

SHAREHOLDERS

 

The
Sapientia Shareholders severally and not jointly nor jointly and severally, represent and warrant to BriaCell as follows:

 

	4.1	Authorization

 

The
Sapientia Shareholders have full power and authority to execute and deliver this Agreement and all other agreements and documents
to be executed and delivered by the Sapientia Shareholders pursuant hereto, and to consummate the transactions contemplated hereby
and thereby. This Agreement and all other agreements and documents to be executed and delivered by the Sapientia Shareholders
pursuant hereto, constitute the valid and binding agreements of the Sapientia Shareholders, enforceable in accordance with their
respective terms.

 

	4.2	No
    Violation

 

Neither
the execution and delivery of this Agreement by the Sapientia Shareholders, nor of any other agreement or document to be executed
and delivered by the Sapientia Shareholders pursuant hereto, nor the consummation by the Sapientia Shareholders of the transactions
contemplated hereby or thereby will constitute a violation of, or be in conflict with, or result in a cancellation of or constitute
a default under, or create (or cause the acceleration of the maturity of) any debt, obligation or liability affecting the Sapientia
Shares owned by the Sapientia Shareholders pursuant to, or result in the creation or imposition of any security interest, lien,
or other encumbrance upon the Sapientia Shares owned by the Sapientia Shareholders under:

 

	 	(a)	any
    contract, agreement, lease or other commitment to which any Sapientia Shareholder is a party or by which any Sapientia Shareholder
    is bound;
	 	 	 
	 	(b)	any
    judgment, decree, order, regulation or rule of any court or governmental authority; or
	 	 	 
	 	(c)	any
    statute or law.

 

	4.3	Share
    Ownership

 

Each
Sapientia Shareholder is the lawful owner of record and beneficially of the number of Sapientia Shares set forth opposite its
or his name in Schedule 2.1(a) hereto, free and clear of all mortgages, liens, pledges, charges, security interests, encumbrances
or other third party interests of any nature whatsoever, including, without limitation, subscriptions, options, warrants, rights
or other agreements granting to any person, firm or corporation any interest in or right to acquire from any Sapientia Shareholder
at any time, or upon the happening of any stated event, any shares (or interests therein) of the Sapientia Shares owned by any
Sapientia Shareholder.

 

    	 	 	 

    	 	-10-	 

    

 

	4.4	Securities
    Law Representations

 

Each
of the Sapientia Shareholder hereby acknowledges and agrees with BriaCell that:

 

	 	(a)	they
    are acquiring the BriaCell Payment Shares for their own account, for investment purposes only and not with a view to any resale,
    distribution or other disposition of the Securities in violation of the United States securities as contemplated by the provisions
    of Section 2(11) of the Securities Act of 1933 (“US Securities Act”);
	 	 	 
	 	(b)	they
    are each an “accredited investor” as such term is defined in Rule 501(a) of Regulation D under the US Securities
    Act;
	 	 	 
	 	(c)	they
    understand (i) the BriaCell Payment Shares have not been and will not be registered under the US Securities Act or the securities
    laws of any state of the United States; and (ii) the sale contemplated hereby is being made in reliance on an exemption from
    such registration requirements;
	 	 	 
	 	(d)	the
    issuance of the BriaCell Payment Shares in exchange therefor will be made pursuant to appropriate from the formal takeover
    bid and registration and prospectus (or equivalent) exemptions of Canadian Securities Laws;
	 	 	 
	 	(e)	the
    certificates representing the BriaCell Payment Shares will bear such legends as required by Securities Laws and the policies
    of the Exchange and it is the responsibility of the Sapientia Shareholder to find out what those restrictions are and to comply
    with them before selling the BriaCell Payment Shares; and
	 	 	 
	 	(f)	they
    are knowledgeable of, or has been independently advised as to, the applicable laws of that jurisdiction which apply to the
    sale of the Sapientia Shares and the issuance of the BriaCell Payment Shares and which may impose restrictions on the resale
    of such BriaCell Payment Shares in that jurisdiction and it is the responsibility of the Sapientia Shareholder to find out
    what those resale restrictions are, and to comply with them before selling the BriaCell Payment Shares.

 

ARTICLE
5

REPRESENTATIONS
AND WARRANTIES OF BRIACELL AND THE ACQUIROR

 

BriaCell
and the Acquiror each jointly represent and warrant to Sapientia and the Shareholders as follows:

 

	5.1	Organization
    and Good Standing

 

	 	(a)	BriaCell
    is a corporation duly organized, validly existing and in good standing under the laws of its province of incorporation, and
    has all requisite corporate power and authority to own or hold under lease its properties and assets and to carry on its business
    as now conducted. BriaCell is duly qualified to do business and is in good standing in every jurisdiction in which a failure
    to so qualify could have a material adverse effect upon its properties, assets, financial condition, results of operation
    or business prospects.

 

    	 	 	 

    	 	-11-	 

    

 

	 	(b)	The
    Acquiror is a corporation duly organized, validly existing and in good standing under the laws of its state of incorporation,
    and has all requisite corporate power and authority to own or hold under lease its properties and assets and to carry on its
    business as now conducted. It is the intention of the parties that Sapientia, following the Closing Date, continue to qualify
    for scientific research and development grants in the United States.

 

	5.2	Authorization

 

Each
of BriaCell and the Acquiror have all requisite power and authority to execute and deliver this Agreement and all other agreements
and documents to be executed and delivered by BriaCell and the Acquiror pursuant hereto and to consummate the transactions contemplated
hereby. The execution and delivery of this Agreement and all other agreements and documents to be executed and delivered by BriaCell
and the Acquiror pursuant hereto, and the consummation of the transactions contemplated hereby and thereby have been duly authorized
by all necessary action on BriaCell’s and the Acquiror’s part and this Agreement and all other agreements and documents
to be executed and delivered by each of BriaCell and the Acquiror pursuant hereto constitute the valid and binding agreements
of BriaCell and the Acquiror enforceable against each of BriaCell and the Acquiror in accordance with their respective terms (subject,
as to the enforcement of remedies, to general principles of equity and to bankruptcy, insolvency and similar laws affecting creditors’
rights generally). Other than the acceptance of the Exchange, no consent of, or notice to, any federal, state or local authority,
or any other person or entity is required to be obtained or made by BriaCell in connection with the execution, delivery and performance
of this Agreement and the other agreements and documents to be executed, delivered and performed by BriaCell pursuant hereto.

 

	5.3	No
    Violation

 

Neither
the execution and delivery of this Agreement, nor the consummation of the transactions contemplated hereby will constitute a violation
of, or be in conflict with, or result in a cancellation of, or constitute a default under, or create (or cause the acceleration
of the maturity of) any debt, obligation or liability affecting, or result in the creation or imposition of any security interest,
lien, or other encumbrance upon any of the assets owned or used by, or any of the capital stock of, BriaCell or the Acquiror under:

 

	 	(a)	any
    term or provision of the certificate of incorporation or by-laws (or other organic document) of BriaCell or the Acquiror;
	 	 	 
	 	(b)	any
    contract, agreement, indenture, lease or other commitment to which BriaCell or the Acquiror are party or by which or the Acquiror
    are bound;
	 	 	 
	 	(c)	any
    judgment, decree, order, regulation or rule of any court or governmental authority; or
	 	 	 
	 	(d)	any
    statute or law.

 

    	 	 	 

    	 	-12-	 

    

 

	5.4	Reporting
    Issuer Status; Listing

 

BriaCell
is a “reporting issuer” under securities legislation in force in each of the provinces of British Columbia and Alberta
is not in default in any material respect of any requirement under such legislation. The BriaCell Shares are listed for trading
on the Exchange.

 

	5.5	Public
    Record

 

All
information and statements filed by or on behalf of BriaCell with applicable securities regulatory authorities were true, correct
and complete in all material respects and did not contain any misrepresentation as of the date of such information or statements,
and BriaCell has not filed any confidential material change reports still maintained on a confidential basis under applicable
securities Laws.

 

	5.6	Share
    Capital

 

	 	(a)	The
    authorized capital of BriaCell consists of an unlimited number of BriaCell Shares, of which 105,867,560 BriaCell Shares are
    issued and outstanding, all of such BriaCell Shares have been duly authorized and validly issued and are outstanding as fully-paid
    and non-assessable shares. The outstanding options, warrants and other convertible securities or rights capable of becoming
    an equity interest in BriaCell are accurately disclosed in the public record. The BriaCell Payment Shares be issued to the
    Sapientia Shareholders in accordance with the terms hereof shall be fully paid, non-assessable shares in the capital of BriaCell.
	 	 	 
	 	(b)	The
    authorized capital of the Acquiror consists of an unlimited number of common stock of which 10,000 shares are currently issued
    and outstanding, all of such shares of the Acquiror have been duly authorized and validly issued and are outstanding as fully-paid
    and non-assessable shares in the capital of the Acquiror. BriaCell is the sole registered and beneficial holder of all of
    the shares in the capital of the Acquiror.

 

	5.7	No
    Significant Acquisition

 

The
transactions contemplated by this Agreement does not constitute a “Significant Acquisition” (as such term is defined
in National Instrument 51-102 – Continuous Disclosure Obligations) by BriaCell.

 

	5.8	MI
    61-101 Exemptions

 

To
the extent that the transactions contemplated by this Agreement constitute a “related-party transaction” (as such
term is defined in Policy 5.9 of the Corporate Finance Manual and under Multilateral Instrument 61-101 – Protection of
Minority Security Holders in Special Transactions (“MI 61-101”)), one or more exemptions are available
from the minority approval and formal valuation requirements prescribed by MI 61-101.

 

    	 	 	 

    	 	-13-	 

    

 

ARTICLE
6

COVENANTS
OF SAPIENTIA

 

Sapientia
covenants and agrees with BriaCell that from the date hereof until the Closing or other termination of this Agreement, without
the prior written consent of BriaCell:

 

	6.1	Operations

 

Except
as otherwise expressly permitted by the terms hereof or as otherwise agreed to in writing by BriaCell:

 

	 	(a)	Sapientia
    shall operate and conduct its business and operate its assets in the normal course of business and in substantial compliance
    with all applicable laws, rules and regulations;
	 	 	 
	 	(b)	Sapientia
    shall maintain and preserve its rights in the Intellectual Property;
	 	 	 
	 	(c)	Sapientia
    shall not create any liability, debt or obligation other than in furtherance of this transaction;
	 	 	 
	 	(d)	Sapientia
    shall not amend any of its constating documents or by-laws; and
	 	 	 
	 	(e)	Sapientia
    shall not take, agree to take, or knowingly permit to be taken any action or do or knowingly permit to be done anything in
    the conduct of its business, or otherwise, which would be contrary to or in breach of any of the terms or provisions of this
    Agreement, or (except as expressly contemplated by this Agreement) which would cause any of the representations, warranties
    or covenants of Sapientia contained herein to be or become untrue.

 

	6.2	Additional
    Information

 

Sapientia
will make available to BriaCell and its authorized agents and accountants for inspection, at reasonable times and under reasonable
circumstances, assets, business and financial records, management reports, all tax returns and working papers of Sapientia, files
and memoranda of their public accountants and outside legal counsel and relevant materials relating its assets or business for
the purpose of making such accounting review, legal and audit investigation or examination deemed desirable by BriaCell.

 

	6.3	Publicity

 

None
of Sapientia, the Sapientia Shareholders or any employee, agent, attorney, officer or public accountant of any Sapientia Shareholder
or BriaCell shall issue any oral or written publicity regarding this transaction without prior consultation with and approval
of BriaCell.

 

    	 	 	 

    	 	-14-	 

    

 

ARTICLE
7 

CONDITIONS
TO CLOSING

 

	7.1	Mutual
    Conditions

 

The
respective obligations of each party to consummate the transactions contemplated by this Agreement shall be subject to the condition
that no suit, action or other proceeding or investigation shall to the knowledge of any party hereto be threatened or pending
before or by any governmental agency or by any third party questioning the legality of this Agreement or the consummation of the
transactions contemplated hereby in whole or in part.

 

	7.2	Conditions
    to the BriaCell’s and the Acquiror’s Obligations

 

The
obligations of BriaCell and the Acquiror to consummate the transactions contemplated by this Agreement shall be subject to the
fulfilment at or prior to the closing (the “Closing”) of each of the following conditions:

 

	 	(a)	All
    representations and warranties made by Sapientia or the Sapientia Shareholders contained in this Agreement, in the Schedules
    or any other written statement, certificate or other instrument furnished to BriaCell by or on behalf of the Sapientia Shareholders
    and Sapientia pursuant to this Agreement, shall be true and correct on the date hereof and as of the Closing Date as though
    such representations and warranties were made as of the Closing Date, and Sapientia and the Sapientia Shareholders shall have
    duly performed or complied with all of the obligations to be performed or complied with by it or him under the terms of this
    Agreement on or prior to Closing.
	 	 	 
	 	(b)	The
    Sapientia Shareholders and Sapientia shall have complied with and performed all agreements, covenants and conditions in this
    Agreement required to be performed and complied with by them on or before the Closing Date, and that all requisite action
    (corporate and other) in order to consummate this Agreement shall have been properly taken by the Sapientia Shareholders and
    Sapientia.
	 	 	 
	 	(c)	No
    material adverse change shall have occurred in the condition (financial or otherwise) of Sapientia, its assets or its business
    considered as a whole.
	 	 	 
	 	(d)	All
    material authorizations, consents, waivers, Approvals or other action required in connection with the execution, delivery
    and performance of this Agreement by the Sapientia Shareholders and the consummation by the Sapientia Shareholders of the
    transactions contemplated hereby shall have been obtained, and Sapientia or the Sapientia Shareholders shall have obtained
    any authorizations, consents, waivers, approvals or other action required in connection with the execution, delivery and performance
    of this Agreement to prevent a material breach or default by Sapientia or the Sapientia Shareholders under any contract to
    which Sapientia or the Sapientia Shareholders is or are a party or for the continuation of any agreement to which Sapientia
    is a party and which relates and is material to the business of  Sapientia.
	 	 	 
	 	(e)	The
    Sapientia Shareholders shall have delivered to BriaCell all instruments of assignment, transfer and conveyance of the Sapientia
    Shares, including, without limitation, properly executed stock powers (assignments separate from certificate) and such other
    closing documents as shall have been reasonably requested by BriaCell, all in form and substance reasonably acceptable to
    Sapientia’s counsel.

 

    	 	 	 

    	 	-15-	 

    

 

	 	(f)	On
    the Closing, provided such persons meet all necessary legal and regulatory requirements and are willing and able to act in
    the positions shown below, the directors and officers of Sapientia shall consist of the following persons:

 

	 	(i)	Dr.
    William Williams (Chief Executive Officer and director);
	 	 	 
	 	(ii)	Martin
    Schmieg (Chief Financial Officer and director); and
	 	 	 
	 	(iii)	James
    Hoffman (Chief Operating Officer).

 

	 	 	Sapientia
    shall take all necessary steps to obtain resignations of existing directors and officers in order for these appointments to
    be effective on Closing.
	 	 	 
	 	(g)	At
    the Closing, Sapientia shall deliver resignations of those directors and officers of Sapientia who are either not continuing
    with Sapientia or are continuing in a different capacity or role, such resignations to include waivers in respect of any liabilities
    of Sapientia to them in a form acceptable to BriaCell, acting reasonably.
	 	 	 
	 	(h)	BriaCell
    shall have received evidence, satisfactory to BriaCell and its counsel, that any unanimous shareholders agreement (if any
    exist) or similar agreement has been terminated on or prior to Closing or, in the alternative, that no unanimous shareholders
    agreement exists.
	 	 	 
	 	(i)	BriaCell
    shall have satisfactorily completed its due diligence review and audit of Sapientia’s books and records and operations.
	 	 	 
	 	(j)	Subject
    to the terms and conditions set forth herein, the parties hereto acknowledge and agree that Sapientia shall be required: (i)
    to deliver the Financial Statements to BriaCell as promptly as reasonably practicable, but in any event no later than 15 days
    after the Closing Date; (ii) notify Faller & Williams Technology LLC of the Closing Date as soon as practicable following
    the date thereof and in any event within 30 days after the Closing Date (collectively, the “Post-Closing Obligations”).
    The Post- Closing Obligations shall be deemed incorporated by reference herein as fully as if set forth herein in their entirely.
    All conditions precedent, representations and covenants contained in this Agreement shall be deemed modified to the extent
    necessary to effect the foregoing.

 

	7.3	Conditions
    to the Sapientia and Sapientia Shareholders’ Obligations

 

The
obligations of the Sapientia Shareholders and Sapientia to consummate the transactions contemplated by this Agreement shall be
subject to the fulfilment at or prior to the Closing of each of the following conditions:

 

	 	(a)	The
    representations and warranties of BriaCell and the Acquiror contained in this Agreement shall be true and correct on the date
    hereof and as of the Closing Date as though such representations and warranties were made as of the Closing Date, and each
    of BriaCell and the Acquiror shall have duly performed or complied with all of the obligations to be performed or complied
    with by it under the terms of this Agreement on or prior to Closing.

 

    	 	 	 

    	 	-16-	 

    

 

	 	(b)	All
    material authorizations, consents, waivers, approvals or other action required in connection with the execution, delivery
    and performance of this Agreement by each of BriaCell and the Acquiror, and the consummation by BriaCell of the transactions
    contemplated hereby, shall have been obtained including the approval of the Exchange.
	 	 	 
	 	(c)	BriaCell
    shall have complied with and performed all agreements, covenants and conditions in this Agreement required to be performed
    and complied with by it on or before the Closing Date, and that all requisite action (corporate and other) in order to consummate
    this Agreement shall have been properly taken by BriaCell.
	 	 	 
	 	(d)	No
    material adverse change shall have occurred in the condition (financial or otherwise) of BriaCell, its assets or its business.

 

ARTICLE
8

TERMINATION

 

	8.1	Termination
    of Agreement

 

This
Agreement and the transactions contemplated hereby may be terminated at any time prior to Closing, as follows:

 

	 	(a)	By
    mutual consent of the parties hereto.
	 	 	 
	 	(b)	By
    BriaCell on the one hand or by Sapientia on the other hand by reason of the breach by the other in any material respect of
    any of its or their representations, warranties, covenants or agreements contained in this Agreement which is not cured within
    five days from the date of written notice of such breach.
	 	 	 
	 	(c)	By
    BriaCell on the one hand or by the Sapientia Shareholders on the other hand if the conditions precedent to their respective
    obligations contained in Sections 7.2 or 7.3 hereof have not been met in all material respects by April 30, 2017 or such later
    date as may be agreed in writing by BriaCell and Sapientia (on its own behalf and on behalf of the Sapientia Shareholders).
	 	 	 
	 	(d)	By
    BriaCell on the one hand or by the Sapientia Shareholders on the other hand if any of the conditions described in Section
    7.1 shall not have been fulfilled by April 30, 2017 or such later date as may be agreed in writing by BriaCell and Sapientia
    (on its own behalf and on behalf of the Sapientia Shareholders).
	 	 	 
	 	(e)	In
    the event of termination of this Agreement by reason of the breach by any party, then the non-offending party shall have full
    recourse for any and all loss, costs, damages or liability suffered or incurred by them as a result of the breach by April
    30, 2017 or such later date as may be agreed in writing by BriaCell and Sapientia (on its own behalf and on behalf of the
    Sapientia Shareholders).

 

    	 	 	 

    	 	-17-	 

    

 

ARTICLE
9

SURVIVAL
OF REPRESENTATIONS AND WARRANTIES

 

The
representations and warranties contained in Article 4 and Article 5 shall survive the Closing Date for a period of 24 months.

 

ARTICLE
10

GENERAL
PROVISIONS

 

	10.1	Waiver
    of Terms

 

Except
as otherwise permitted or required hereunder, any of the terms or conditions of this Agreement may be waived at any time by the
party or parties entitled to the benefit thereof only by a written notice signed by the party or parties waiving such terms or
conditions.

 

	10.2	Amendment
    of Agreement

 

Except
as otherwise permitted or required hereunder, this Agreement may be amended, supplemented or interpreted at any time only by written
instrument duly executed by each of the Sapientia Shareholders, Sapientia and BriaCell.

 

	10.3	Payment
    of Expenses

 

The
Sapientia Shareholders and BriaCell shall each pay their or its own expenses, including, without limitation, the expenses of their
or its own counsel, investment bankers and accountants, incurred in connection with the preparation, execution and delivery of
this Agreement and the other agreements and documents referred to herein and the consummation of the transactions contemplated
hereby and thereby.

 

	10.4	Contents
    of Agreement, Parties in Interest, Assignment

 

This
Agreement and the other agreements and documents referred to herein set forth the entire understanding of the parties with respect
to the subject matter hereof. Any previous agreements or understandings between the parties regarding the subject matter hereof
are superseded by this Agreement. All representations, warranties, covenants, terms and conditions of this Agreement shall be
binding upon and inure to the benefit of and be enforceable by the respective heirs, legal representatives, successors and permitted
assigns of the parties hereto.

 

	10.5	Independent
    Legal Advice

 

EACH
OF THE PARTIES TO THIS AGREEMENT ACKNOWLEDGES AND AGREES THAT BENNETT JONES LLP HAS ACTED AS COUNSEL ONLY TO BRIACELL AND THAT
BENNETT JONES LLP IS NOT PROTECTING THE RIGHTS AND INTERESTS OF SAPIENTIA OR THE SAPIENTIA SHAREHOLDERS. SAPIENTIA AND THE SAPIENTIA
SHAREHOLDERS ACKNOWLEDGE AND AGREE THAT BRIACELL AND BENNETT JONES LLP HAVE GIVEN THEM THE OPPORTUNITY TO SEEK INDEPENDENT LEGAL
ADVICE WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT AND, FURTHER, THE SAPIENTIA SHAREHOLDERS HEREBY REPRESENT AND WARRANT
TO THE ACQUIROR, BRIACELL, SAPIENTIA, AND BENNETT JONES LLP THAT THEY HAVE SOUGHT INDEPENDENT LEGAL ADVICE OR WAIVE SUCH ADVICE.

 

    	 	 	 

    	 	-18-	 

    

 

	10.6	Notices

 

All
notices, requests, demands and other communications required or permitted to be given hereunder shall be by hand-delivery, e-mail,
certified or registered mail, return receipt requested; telex, telecopier, or next day air courier to the parties set forth below.
Such notices shall be deemed given: at the time personally delivered, if delivered by hand; three days after deposit in the Canadian
mail, if sent by registered mail; upon delivery, with receipt acknowledged, if telecopied; and the next business day after timely
delivery to the courier, if sent by courier.

 

If
to BriaCell or the Acquiror:

 

Suite
300 – 235 15th Street

West
Vancouver, British Columbia V7T 2X1

 

	 	Attention:	Dr.
    Saied Babaei, Chairman
	 	 	 
	 	E-mail:	sbabaei@briacell.com

 

With
a copy to:

 

Bennett
Jones LLP

100
King Street West

One
First Canadian Place, Suite 3400

Toronto,
Ontario M4X 1A4

 

	 	Attention:	Aaron
    Sonshine, Partner
	 	 	 
	 	E-mail:	sonshinea@bennettjones.com

 

If
to Sapientia and the Sapientia Shareholders:

 

Suite
303 - 2015 N. Federal Hwy

Delray
Beach, Florida 33483

 

	 	Attention:	Dr.
    William Williams 
	 	 	 
	 	E-mail:	wiliams@briacell.com

 

Any
party hereto may change its notice address by proper notice to the other parties.

 

	10.7	Severability

 

In
the event that any one or more of the provisions contained in this Agreement shall be invalid, illegal or unenforceable in any
respect for any reason, the validity, legality and enforceability of any such provision in every other respect and of the remaining
provisions of this Agreement shall not be in any way impaired.

 

    	 	 	 

    	 	-19-	 

    

 

	10.8	Counterparts

 

This
Agreement may be executed (by original, fax or other electronic transmission) in two or more counterparts, each of which shall
be deemed an original, but all of which together shall constitute one and the same instrument.

 

	10.9	Headings

 

The
headings of the Sections and the subsections of this Agreement are inserted for convenience of reference only and shall not constitute
a part hereof.

 

	10.10	Governing
    Law; Jurisdiction

 

This
Agreement shall, in all respects, be subject to, interpreted, construed and enforced in accordance with and under the laws of
the Province of British Columbia and applicable laws of Canada.

 

	10.11	Attornment

 

The
parties each attorn to the non-exclusive jurisdiction of the courts of the Province of British Columbia.

 

	10.12	Instruments
    of Further Assurance

 

Each
of the parties hereto agrees, upon the request of any of the other parties hereto, from time to time to execute and deliver to
such other party or parties all such instruments and documents of further assurance or otherwise as shall be reasonable under
the circumstances, and to do any and all such acts and things as may reasonably be required to carry out the obligations of such
requested party hereunder.

 

	10.13	Currency

 

All
monetary amounts expressed in this Agreement and all payments required by this Agreement are and shall be in Canadian dollars.

 

[Remainder
of page intentionally left blank]

 

    	 	 	 

     

    

 

IN
WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto on the day and year first above written.

 

SIGNED,
SEALED & DELIVERED

in
the presence

 

		 	
	Witness	 	Dr.
    William Williams
	 	 	 
	 	 	 
	Witness	 	James
    Hoffman
	 	 	 
	 	 	 
	Witness	 	Martin
    Schmieg
	 	 	 
	 	 	 
	Witness	 	Douglas
    Faller
	 	 	 
	 	 	 
	Witness	 	Robert
    Williams
	 	 	 
	 	 	 
	Witness	 	Edward
    McKeever
	 	 	 
	 	 	 
	Witness	 	Susan
    Erickson Viitanen
	 	 	 
	 	 	 
	Witness	 	Shui
    He

 

Signature
Page to Share Exchange Agreement

 

    	 	 	 

     

    

 

IN
WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto on the day and year first above written.

 

SIGNED,
SEALED & DELIVERED

in
the presence

 

		 	
	Witness	 	Dr.
    William Williams
	 	 	 
		 	
	Witness	 	James
    Hoffman
	 	 	 
	 	 	 
	Witness	 	Martin
    Schmieg
	 	 	 
	 	 	 
	Witness	 	Douglas
    Faller
	 	 	 
	 	 	 
	Witness	 	Robert
    Williams
	 	 	 
	 	 	 
	Witness	 	Edward
    McKeever
	 	 	 
	 	 	 
	Witness	 	Susan
    Erickson Viitanen
	 	 	 
	 	 	 
	Witness	 	Shui
    He

 

Signature
Page to Share Exchange Agreement

 

    	 	 	 

     

    

 

IN
WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto on the day and year first above written.

 

SIGNED,
SEALED & DELIVERED

in
the presence

 

	 	 	 
	Witness	 	Dr.
    William Williams
	 	 	 
	 	 	 
	Witness	 	James
    Hoffman
	 	 	 
		 	
	Witness	 	Martin
    Schmieg
	 	 	 
	 	 	 
	Witness	 	Douglas
    Faller
	 	 	 
	 	 	 
	Witness	 	Robert
    Williams
	 	 	 
	 	 	 
	Witness	 	Edward
    McKeever
	 	 	 
	 	 	 
	Witness	 	Susan
    Erickson Viitanen
	 	 	 
	 	 	 
	Witness	 	Shui
    He

 

Signature
Page to Share Exchange Agreement

 

    	 	 	 

     

    

 

IN
WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto on the day and year first above written.

 

SIGNED,
SEALED & DELIVERED

in
the presence

 

	 	 	 
	Witness	 	Dr.
    William Williams
	 	 	 
	 	 	 
	Witness	 	James
    Hoffman
	 	 	 
	 	 	 
	Witness	 	Martin
    Schmieg
	 	 	 
		 	
	Witness	 	Douglas
    Faller
	 	 	 
	 	 	 
	Witness	 	Robert
    Williams
	 	 	 
	 	 	 
	Witness	 	Edward
    McKeever
	 	 	 
	 	 	 
	Witness	 	Susan
    Erickson Viitanen
	 	 	 
	 	 	 
	Witness	 	Shui
    He

 

Signature
Page to Share Exchange Agreement

 

    	 	 	 

     

    

 

IN
WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto on the day and year first above written.

 

SIGNED,
SEALED & DELIVERED

in
the presence

 

	 	 	 
	Witness	 	Dr.
    William Williams
	 	 	 
	 	 	 
	Witness	 	James
    Hoffman
	 	 	 
	 	 	 
	Witness	 	Martin
    Schmieg
	 	 	 
	 	 	 
	Witness	 	Douglas
    Faller
	 	 	 
		 	
	Witness	 	Robert
    Williams
	 	 	 
	 	 	 
	Witness	 	Edward
    McKeever
	 	 	 
	 	 	 
	Witness	 	Susan
    Erickson Viitanen
	 	 	 
	 	 	 
	Witness	 	Shui
    He

 

Signature
Page to Share Exchange Agreement

 

    	 	 	 

     

    

 

IN
WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto on the day and year first above written.

 

SIGNED,
SEALED & DELIVERED

in
the presence

 

	 	 	 
	Witness	 	Dr.
    William Williams
	 	 	 
	 	 	 
	Witness	 	James
    Hoffman
	 	 	 
	 	 	 
	Witness	 	Martin
    Schmieg
	 	 	 
	 	 	 
	Witness	 	Douglas
    Faller
	 	 	 
	 	 	 
	Witness	 	Robert
    Williams
	 	 	 
		 	
	Witness	 	Edward
    McKeever
	 	 	 
	 	 	 
	Witness	 	Susan
    Erickson Viitanen
	 	 	 
	 	 	 
	Witness	 	Shui
    He

 

Signature
Page to Share Exchange Agreement

 

    	 	 	 

     

    

 

IN
WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto on the day and year first above written.

 

SIGNED,
SEALED & DELIVERED

in
the presence

 

	 	 	 
	Witness	 	Dr.
    William Williams
	 	 	 
	 	 	 
	Witness	 	James
    Hoffman
	 	 	 
	 	 	 
	Witness	 	Martin
    Schmieg
	 	 	 
	 	 	 
	Witness	 	Douglas
    Faller
	 	 	 
	 	 	 
	Witness	 	Robert
    Williams
	 	 	 
	 	 	 
	Witness	 	Edward
    McKeever
	 	 	 
		 	
	Witness	 	Susan
    Erickson Viitanen
	 	 	 
	 	 	 
	Witness	 	Shui
    He

 

Signature
Page to Share Exchange Agreement

 

    	 	 	 

     

    

 

IN
WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto on the day and year first above written.

 

SIGNED,
SEALED & DELIVERED

in
the presence

 

	 	 	 
	Witness	 	Dr.
    William Williams
	 	 	 
	 	 	 
	Witness	 	James
    Hoffman
	 	 	 
	 	 	 
	Witness	 	Martin
    Schmieg
	 	 	 
	 	 	 
	Witness	 	Douglas
    Faller
	 	 	 
	 	 	 
	Witness	 	Robert
    Williams
	 	 	 
	 	 	 
	Witness	 	Edward
    McKeever
	 	 	 
	 	 	 
	Witness	 	Susan
    Erickson Viitanen
	 	 	 
		 	
	Witness	 	Shui
    He

 

Signature
Page to Share Exchange Agreement

 

    	 	 	 

     

    

 

		 	
	Witness	 	Kevin
    Hou
	 	 	 
	 	 	 
	Witness	 	John
    Hand
	 	 	 
	 	 	 
	Witness	 	Mike
    Tomas
	 	 	 
	 	 	 
	Witness	 	James
    Seibold
	 	 	 
	 	 	 
	Witness	 	Maria
    Trojanowska
	 	 	 
	 	 	 
	Witness	 	Steven
    Krivicich

 

	BRIACELL
    THERAPEUTICS CORP.	 
	 	 	 
	Per:	 	 
	 	Authorized
    Signing Officer	 
	 	 	 
	BRIACELL
    THERAPEUTICS CORP.	 
	 	 	 
	Per:	 	 
	 	Authorized
    Signing Officer	 

 

Signature
Page to Share Exchange Agreement

 

    	 	 	 

     

    

 

	 	 	 
	Witness	 	Kevin
    Hou
	 	 	 
		 	
	Witness	 	John
    Hand
	 	 	 
	 	 	 
	Witness	 	Mike
    Tomas
	 	 	 
	 	 	 
	Witness	 	James
    Seibold
	 	 	 
	 	 	 
	Witness	 	Maria
    Trojanowska
	 	 	 
	 	 	 
	Witness	 	Steven
    Krivicich

 

	BRIACELL
    THERAPEUTICS CORP.	 
	 	 	 
	Per:	 	 
	 	Authorized
    Signing Officer	 
	 	 	 
	BRIACELL
    THERAPEUTICS CORP.	 
	 	 	 
	Per:	 	 
	 	Authorized
    Signing Officer	 

 

Signature
Page to Share Exchange Agreement

 

    	 	 	 

     

    

 

	 	 	 
	Witness	 	Kevin
    Hou
	 	 	 
	 	 	 
	Witness	 	John
    Hand
	 	 	 
		 	
	Witness	 	Mike
    Tomas
	 	 	 
	 	 	 
	Witness	 	James
    Seibold
	 	 	 
	 	 	 
	Witness	 	Maria
    Trojanowska
	 	 	 
	 	 	 
	Witness	 	Steven
    Krivicich

 

	BRIACELL
    THERAPEUTICS CORP.	 
	 	 	 
	Per:	 	 
	 	Authorized
    Signing Officer	 
	 	 	 
	BRIACELL
    THERAPEUTICS CORP.	 
	 	 	 
	Per:	 	 
	 	Authorized
    Signing Officer	 

 

Signature
Page to Share Exchange Agreement

 

    	 	 	 

     

    

 

	 	 	 
	Witness	 	Kevin
    Hou
	 	 	 
	 	 	 
	Witness	 	John
    Hand
	 	 	 
	 	 	 
	Witness	 	Mike
    Tomas
	 	 	 
		 	
	Witness	 	James
    Seibold
	 	 	 
	 	 	 
	Witness	 	Maria
    Trojanowska
	 	 	 
	 	 	 
	Witness	 	Steven
    Krivicich

 

	BRIACELL
    THERAPEUTICS CORP.	 
	 	 	 
	Per:	 	 
	 	Authorized
    Signing Officer	 
	 	 	 
	BRIACELL
    THERAPEUTICS CORP.	 
	 	 	 
	Per:	 	 
	 	Authorized
    Signing Officer	 

 

Signature
Page to Share Exchange Agreement

 

    	 	 	 

     

    

 

	 	 	 
	Witness	 	Kevin
    Hou
	 	 	 
	 	 	 
	Witness	 	John
    Hand
	 	 	 
	 	 	 
	Witness	 	Mike
    Tomas
	 	 	 
	 	 	 
	Witness	 	James
    Seibold
	 	 	 
		 	
	Witness	 	Maria
    Trojanowska
	 	 	 
	 	 	 
	Witness	 	Steven
    Krivicich

 

	BRIACELL
    THERAPEUTICS CORP.	 
	 	 	 
	Per:	 	 
	 	Authorized
    Signing Officer	 
	 	 	 
	BRIACELL
    THERAPEUTICS CORP.	 
	 	 	 
	Per:	 	 
	 	Authorized
    Signing Officer	 

 

Signature
Page to Share Exchange Agreement

 

    	 	 	 

     

    

 

	 	 	 
	Witness	 	Kevin
    Hou
	 	 	 
	 	 	 
	Witness	 	John
    Hand
	 	 	 
	 	 	 
	Witness	 	Mike
    Tomas
	 	 	 
	 	 	 
	Witness	 	James
    Seibold
	 	 	 
	 	 	 
	Witness	 	Maria
    Trojanowska
	 	 	 
	 	 	
	Witness	 	Steven
    Krivicich

 

	BRIACELL
    THERAPEUTICS CORP.	 
	 	 	 
	Per:	 	 
	 	Authorized
    Signing Officer	 
	 	 	 
	BRIACELL
    THERAPEUTICS CORP.	 
	 	 	 
	Per:	 	 
	 	Authorized
    Signing Officer	 

 

Signature
Page to Share Exchange Agreement

 

    	 	 	 

     

    

 

	 	 	 
	Witness	 	Kevin
    Hou
	 	 	 
	 	 	 
	Witness	 	John
    Hand
	 	 	 
	 	 	 
	Witness	 	Mike
    Tomas
	 	 	 
	 	 	 
	Witness	 	James
    Seibold
	 	 	 
	 	 	 
	Witness	 	Maria
    Trojanowska
	 	 	 
	 	 	 
	Witness	 	Steven
    Krivicich

 

	BRIACELL
    THERAPEUTICS CORP.	 
	 	 	 
	Per:		 
	 	Authorized
    Signing Officer	 
	 	 	 
	BRIACELL
    THERAPEUTICS CORP.	 
	 	 	 
	Per:	 	 
	 	Authorized
    Signing Officer	 
	 	 	 
	SAPIENTIA
    PHARMACEUTICALS, INC.	 
	 	 
	Per:		 
	 	Authorized
    Signing Officer	 

 

Signature
Page to Share Exchange Agreement

 

    	 	 	 

     

    

 

EXHIBIT
“A”

 

	1.	Dr.
    William Williams
	 	 
	2.	James
    Hoffman
	 	 
	3.	Martin
    Schmieg
	 	 
	4.	Douglas
    Faller
	 	 
	5.	Robert
    Williams
	 	 
	6.	Edward
    McKeever
	 	 
	7.	Susan
    Erickson Viitanen
	 	 
	8.	Shui
    He
	 	 
	9.	Kevin
    Hou
	 	 
	10.	John
    Hand
	 	 
	11.	Mike
    Tomas
	 	 
	12.	James
    Seibold
	 	 
	13.	Maria
    Trojanowska
	 	 
	14.	Steven
    Krivicich

 

    	 	 	 

     

    

 

SCHEDULE
2.1(A)

 

SAPIENTIA
SHARES

 

	Name
                                         of Sapientia

        Shareholder
	 	Sapientia
                                         Shares

                                                                                Owned
	 	Percentage
                                         of Total Sapientia

        Shares
        Owned

	 	 	 	 	 
	Dr.
    William Williams	 	2,052,653	 	49.5%
	 	 	 	 	 
	James
    Hoffman	 	1,051,000	 	25.4%
	 	 	 	 	 
	Martin
    Schmieg	 	120,000	 	2.9%
	 	 	 	 	 
	Douglas
    Faller	 	406,750	 	9.8%
	 	 	 	 	 
	Robert
    Williams	 	406,750	 	9.8%
	 	 	 	 	 
	Edward
    McKeever	 	5,000	 	0.1%
	 	 	 	 	 
	Susan
    Erickson Viitanen	 	5,000	 	0.1%
	 	 	 	 	 
	Shui
    He	 	10,000	 	0.2%
	 	 	 	 	 
	Kevin
    Hou	 	10,000	 	0.2%
	 	 	 	 	 
	John
    Hand	 	10,000	 	0.2%
	 	 	 	 	 
	Mike
    Tomas	 	10,000	 	0.2%
	 	 	 	 	 
	James
    Seibold	 	6,000	 	0.1%
	 	 	 	 	 
	Maria
    Trojanowska	 	50,000	 	1.2%
	 	 	 	 	 
	Steven
    Krivicich	 	1,000	 	0.0%
	 	 	 	 	 
	TOTAL:	 	4,144,153	 	100%

 

    	 	 	 

     

    

 

SCHEDULE
3.9 

 

CONTRACTS

 

	1.	License
    Agreement dated March 16, 2017 by and between Sapientia Pharmaceuticals, Inc. and Faller & Williams Technology LLC.

 

    	 	 	 

     

    

 

SCHEDULE
3.13 

 

PATENTS,
ETC.

 

	1.	U.S.
    Provisional Application No. 61/703,081 entitle “PKC Delta Inhibitors for use as Therapeutics” filed 19 September
    2012 .
	 	 
	2.	International
    Application No. PCT/US2013/60638 entitled “PKC Delta Inhibitors for use as Therapeutics” filed 19 September 2013.
	 	 
	3.	U.S.
    Patent No. 9,364,460 entitled “PKC Delta Inhibitors for use as Therapeutics” issued 14 June 2016.
	 	 
	4.	U.S.
    Patent Application No. 15/148,420 entitled “PKC Delta Inhibitors for use as Therapeutics” filed 06 May 2016.
	 	 
	5.	U.S.
    Patent Application No. 15/425,381 entitled “PKC Delta Inhibitors for use as Therapeutics” filed 06 February 2017.
	 	 
	6.	EP
    Patent Application No. 13839158.6 “PKC Delta Inhibitors for use as Therapeutics” filed 25 March 2015.CLINICAL
STUDY AGREEMENT

 

This
Clinical Study Agreement (the “Agreement”) is entered into by and between BriaCell Therapeutics Corporation (the “Sponsor”),
a publicly traded corporation with a principal place of business located at 820 Heinz Avenue, Berkeley, California 94710, and
Cancer Insight, LLC (the “CRO”), a Texas limited liability company with a principal place of business located at 110
East Houston Street, San Antonio, Texas 78205 (each a “Party” and collectively, the “Parties”).

 

The
Study, which is identified as “A Phase I/IIa Rollover Study of the Whole-Cell Vaccine BriaVaxTM in Metastatic or Locally
Recurrent Breast Cancer Patients in Combination with Ipilimumab or Pembrolizumab,” and the Protocol, which is identified
as “BRI-ROL-001,” have both been developed by the Sponsor. The Sponsor has engaged the CRO to conduct the Study and
administer the Protocol. The CRO is responsible for the general conduct of the Study.

 

The
Agreement shall be made effective as of the last day of signature (“Effective Date”). The Parties agree as follows:

 

ARTICLE
1 – SCOPE OF WORK

 

1.1
CRO and the Overall Principal Investigator named by CRO and all Site Principal Investigator(s) and Sub-Investigators (the
Overall Principal Investigator named by the CRO, and all Site Principal Investigator(s), and all Sub-Investigators are each
an “Investigator” and collectively the “Investigators”) shall, to the best of their efforts, perform
their respective obligations under the Study in accordance with this Agreement. All procedures required for directing and
monitoring the Study are delineated in Exhibit A - Protocol.

 

1.2
Sponsor shall be responsible for providing any and all necessary study drugs (the “Study Drug”) for each Study
Subject (as that term is defined in 21 C.F.R. Section 312.3(b), means a human being who participates in the Study), assuring
its purity and sterility, and providing and shipping it to the Study Site(s) (defined as any hospital(s) or similar
institution(s) participating in the Study) for this Study.

 

1.3
Investigators will accurately complete and deliver to Sponsor through CRO a signed Statement of Investigator Form FDA 1572,
the Investigators’ current curriculum vitae, a copy of the Investigators’ current medical license, and that
Investigators agree to notify Sponsor, through CRO, immediately if there is any change to such signed Statement of
Investigator Form FDA 1572.

 

1.4
Through CRO, the Investigators connected with the Study shall complete and return to Sponsor the required financial
disclosure certification prior to the initiation of the Study in order to ensure compliance with 21 C.F.R. § 54. Through
CRO, the Investigators shall promptly notify Sponsor of any change in the accuracy of the financial disclosure certification
during the term of this Agreement and promptly notify Sponsor of any change in the accuracy of the financial disclosure
certification after the termination or expiration of this Agreement and for one (1) year following completion of the Study.
In addition, CRO shall comply with all applicable regulatory requirements regarding reporting and management of the conflicts
of interest.

 

    	 	1	 

     

    

 

1.5
Investigators must obtain all necessary approvals from all applicable authorities that are responsible for the oversight of
the conduct of the Study.

 

1.6
It is anticipated that the Study will commence on or around “2017 October 15” (the “Start Date”) and
it is anticipated that the Study will be completed on or around “2019 October 16” (the “End Date”),
unless otherwise terminated in accordance with this Agreement.

 

1.7
CRO represents and warrants that, to the best of its knowledge, neither it, nor any of its employees or agents performing
hereunder, have ever been and/or are currently the subject of a proceeding that could lead to it or such employees or agents
becoming debarred or disqualified pursuant to 21 C.F.R. § 312.70. CRO further covenants that if, during the term of this
Agreement, it, or it becomes reasonably aware that any of its employees or agents performing hereunder, become or are the
subject of a proceeding that could lead to that party becoming debarred or disqualified pursuant to 21 C.F.R. §
312.70, CRO shall notify Sponsor as soon as reasonably possible, and Sponsor shall have the right to immediately terminate
this Agreement.

 

1.8
Details regarding the specific scope of services, Party responsibilities, and Party duties can be found in the Detailed
Budget, which shall be incorporated herein and made part hereof.

 

ARTICLE
2 – COSTS AND PAYMENTS

 

2.1
Sponsor shall provide financial support for the Study in accordance with the approved budget (the “Budget”) set
forth in Exhibit B. Such financial support shall not exceed the amount in Exhibit B unless agreed to in advance by both
Parties in writing. If, at any point during the course of the Study, the costs and/or expenses of the Study exceed the
amounts as contemplated in the Budget, CRO shall submit, in writing, Change Orders and the Parties will negotiate such Change
Orders in good faith. Change Orders shall become binding if, and only if, agreed to by both Parties in writing.

 

2.2
Unless otherwise identified in Exhibit B, Sponsor shall pay CRO in accordance with Exhibit B within thirty (30) days of
receipt of invoices from CRO.

 

2.3
If a Study Subject discontinues participation in the Study, Sponsor shall reimburse CRO for all non-cancelable obligations
and actual expenses incurred in connection with the Subject through the date of the Subject’s withdrawal from the
Study. CRO, to the best of its ability, will ensure that Investigators only enroll Study Subjects who meet eligibility
criteria and will endeavor to select Study Subjects likely to complete the Study so as to minimize the risk and losses to
Sponsor caused by the untimely withdrawal of Study Subjects from the Study.

 

    	 	2	 

     

    

 

2.4
Sponsor shall, whenever feasible and unless otherwise instructed by CRO, make payments to CRO via ACH transfer or wire
transfer under the following directions:

 

Broadway
Bank

1177 NE Loop 410

San
Antonio, TX 78209

ABA/Routing Number - 114021933

Receiving
Party - Cancer Insight, LLC

Receiving Account - 4100041547

 

2.5
When an ACH transfer or wire transfer is not reasonably feasible, Sponsor shall make payments via check and shall make all
checks payable to Cancer Insight, LLC and forward them to the following address:

 

Cancer
Insight, LLC

Attn:
Accounts Receivable

110 East Houston Street

San Antonio, Texas 78205

 

2.6
To ensure proper crediting by CRO, documentation supporting each payment shall include the title of the Study and the
corresponding invoice identification number.

 

ARTICLE
3 – INDEPENDENT CONTRACTORS

 

3.1
Sponsor and CRO are independent contractors, and this Agreement shall not be construed to constitute a partnership or joint
venture between or among any of the Parties or make any one Party the agent or employee of any other Party. No Party shall
hold itself out contrary to the terms of this provision, and no Party shall become liable for any representation, act, and/or
omission of another Party contrary to the terms hereof.

 

ARTICLE
4 – COMPLIANCE WITH LAW AND ACCEPTED PRACTICE

 

4.1
The Parties intend to conduct their relationship in compliance with all applicable laws, including, but not limited to, the
Medicare/Medicaid Anti-Fraud and Abuse Amendments and the prohibition on physician self-referral. In the event of a change in
and/or interpretation of governing law, the Parties shall modify this Agreement and/or their practices to comply with such
legal requirements.

 

4.2
Investigators and CRO shall perform their respective obligations under the Study in conformance with, as applicable,
generally accepted standards of good clinical practice, the applicable Protocol, reasonable instructions provided by Sponsor,
and all applicable local, state, and federal laws and regulations governing the performance of clinical investigations
including, but not limited to, the Federal Food, Drug and Cosmetic Act and regulations of the Food and Drug Administration
(the “FDA”).

 

    	 	3	 

     

    

 

4.3
CRO will ensure that all records resulting from the Study are retained in accordance with applicable regulatory requirements
until at least two (2) years have elapsed since the formal discontinuation of clinical development of the investigational
drug. Sponsor shall pay any applicable record storage fees.

 

4.4
Investigators, through CRO, will keep Sponsor informed regularly of all material communications regarding the Study with any
regulatory agencies.

 

4.5
CRO shall provide, at least thirty (30) days prior, written notice to Sponsor of its intention to re-locate or destroy
records resulting from the Study. Upon expiration of such notice period, all such records shall be re-located, returned,
and/or destroyed pursuant to the procedure as set forth in the applicable protocol or as directed in writing by Sponsor
before the expiration of such notice period.

 

ARTICLE
5 – MONITORING OF STUDY

 

5.1
During the term of this Agreement, CRO agrees to permit representatives of Sponsor and/or the FDA to reasonably examine, upon
reasonable prior notice and at a mutually agreeable time during normal business hours, and subject to compliance with rules
and regulations applicable to the Study sites, Study Subjects, and any applicable duties of confidentiality and
nondisclosure, information reasonably necessary to confirm that the Study is being conducted in conformance with the
applicable Protocol and in compliance with applicable FDA and Drug Enforcement Administration (the “DEA”) laws
and regulations.

 

5.2
CRO shall notify Sponsor promptly if it becomes aware the FDA or the DEA schedules or, without scheduling, begins an
inspection.

 

5.3
CRO shall notify Sponsor within a reasonable period and in writing, of any severe and life threatening or unexpected severe
adverse reaction experienced by any Study Subjects that are, to the best of their knowledge, are a result of participating in
the Study. Sponsor agrees to assume responsibility for any associated liability and the reasonable costs of treatment of any
adverse reaction and/or injury to Study Subjects, which is in accord with Section 12.7 of this Agreement.

 

    	 	4	 

     

    

 

ARTICLE
6 – CONFIDENTIAL INFORMATION

 

6.1
“Confidential Information” means any and all information and material which is confidential in nature,
proprietary to, and/or is a trade secret of one Party (the “Disclosing Party”), and/or information the Disclosing
Party provides regarding third parties, whether or not marked or otherwise identified as “confidential” or
“proprietary”, and which is disclosed to or obtained by the other Party (the “Receiving Party”) or
its representatives in connection with this Agreement, whether in written, oral, magnetic, optical, and/or other form, except
any such materials and/or information that:

 

		a.	is
                                         now or hereafter becomes part of the public domain through no fault of the Receiving
                                         Party;

 

		b.	is
                                         known to the Receiving Party without a confidentiality obligation before the Effective
                                         Date of this Agreement and can be documented as such;

 

		c.	is
                                         obtained by the Receiving Party from a third party who has no obligation to maintain
                                         the materials or information in confidence;

 

		d.	is
                                         independently developed by the Receiving Party and can be documented as such;

 

		e.	has
                                         been made available by its owner to others without a confidentiality obligation;

 

		f.	relates
                                         to potential hazards or cautionary warnings associated with the production, handling,
                                         and/or use of the Study Drug; and/or

 

		g.	constitutes
                                         an annual report to the FDA.

 

6.2
Receiving Party shall hold the Confidential Information in complete confidence and shall not, without the express
prior written consent of Disclosing Party, disclose, produce, publish, permit access to, or reveal the Confidential
Information disclosed hereunder to any third party other than Receiving Party’s Representatives who have a need to know
such information for the purpose of this Agreement and who are bound by obligations of confidentiality and non-use that are
at least as restrictive as those set forth in this Agreement. Except as provided in Article 8, the Parties shall use the
same degree of care, but no less than a reasonable degree of care, as it uses to protect its own Confidential Information,
which in no event shall be less than a reasonable standard of care, for a period extending until ten (10) years after
termination or expiration of this Agreement, to prevent disclosure and/or unauthorized use of the other Party’s
Confidential Information without such Party’s prior written consent.

 

    	 	5	 

     

    

 

6.3
Notwithstanding anything to the contrary contained herein, the Receiving Party, shall be entitled to:

 

		a.	disclose
                                         the Confidential Information of the Disclosing Party as required to be disclosed pursuant
                                         to law, regulation, and/or court order, including disclosures in connection with any
                                         regulatory approval process, provided that the Receiving Party shall:

 

		i.	notify
                                         the Disclosing Party of any such disclosure requirement as soon as reasonably possible;

 

		ii.	cooperate
                                         with the Disclosing Party, at the Disclosing Party’s expense, if the Disclosing
                                         Party seeks a protective order or other remedy in respective of any such disclosure;
                                         and

 

		iii.	furnish
                                         only that portion of the Confidential Information which the Receiving Party is legally
                                         required to disclose

 

		b.	use
                                         the Confidential Information of the Disclosing Party to treat Study Subjects participating
                                         in the Study.

 

6.4
Sponsor shall comply with all laws, regulations, and common law relating to Study Subject privacy, patient privacy, and the
confidentiality of medical information. Without limiting the foregoing, Sponsor shall keep confidential and shall not use or
disclose any “protected health information” as defined in the Health Insurance Portability and Accountability Act
of 1996, 42 U.S.C. § 1320d, et seq. and regulations and official guidance promulgated thereunder (collectively,
“HIPAA”), except in accordance with the authorization signed by the Study Subject and/or patient, as that term is
applicable.

 

6.5
Sponsor shall not use any information obtained in connection with this Agreement to contact Study Subject and/or patients, as
that term is applicable, and/or for marketing purposes.

 

6.6
Sponsor shall exclusively own all clinical data gathered during the Study to be used by Sponsor for whatever purpose in
compliance with applicable privacy laws. Clinical data may be used by the owner of the IND for all regulatory filings
required by the FDA or other governmental body.

 

6.7
Sponsor’s use of de-identified clinical data shall be exempt from the duties of confidentiality imposed by Article
6. Investigators shall have a license to use de- identified clinical data solely to publish such data from the Study Subject
to the provisions of this Agreement.

 

6.8
Notwithstanding the foregoing and/or any other provision of this Agreement, the Investigators shall have the right to
disclose to a Study Subject participating in the Study any information concerning the Study Subject contained in his/her
medical records, and the Study Subject shall have the right to use that information for noncommercial purposes.

 

    	 	6	 

     

    

 

ARTICLE
7 – RECORDS AND REPORTING

 

7.1
CRO shall reasonably maintain complete, current, and accurate records of the status and progress of the Study, all Study
Subject information, and all other applicable and relevant data and information related to the Study, including but not
limited to Case Report Forms (“CRFs”), Informed Consent Forms (“ICFs”), Investigators Study notebook,
original source documents for Study Subjects, including but not limited to lab reports, hospital charts, pharmacy records,
ECGs, x-rays, radiology reports, and biopsy reports, Study Drug disposition forms, and any documents deemed essential
documents as defined by ICH Guideline for Good Clinical Practice Section 8 (“Study Documentation”) and shall
provide such documents, data, and/or information to Sponsor upon reasonable request.

 

7.2
At Sponsor’s reasonable request, CRO shall advise Sponsor of the status of the Study through regular telephone
conversations, written correspondence, and/or meetings, at Sponsor’s expense if meeting location is outside San
Antonio, Texas, with Sponsor.

 

ARTICLE
8 – PUBLICATION

 

8.1
General Procedures. Notwithstanding any other provision contained in this Agreement, Investigators shall have the right
to publish, in scientific journals, the de- identified clinical data generated from the Study, subject to the Sponsor’s
need to protect it’s vital and proprietary information. CRO and/or Investigators shall furnish Sponsor with a copy of any
proposed publication of material at least thirty (30) days in advance of submission of the manuscript for the publication date.
CRO and/or Investigators acknowledge that Sponsor has a proprietary and vital interest in such data and hereby grants Sponsor
the right to review the proposed publication. If Sponsor fails to contact the Investigators with suggested revisions, including,
but not limited to, the redaction of any Sponsor Confidential Information or information deemed harmful to the Sponsor within
thirty (30) days following receipt of such publication, then Investigators may immediately submit such publication without further
obligation to Sponsor regarding its right to review. The Investigators shall give Sponsor the option of receiving acknowledgement
in such publications for its sponsorship. If requested in writing by either Party, CRO, Investigators, and/or Sponsor shall withhold
such submission for publication an additional sixty (60) days to allow for filing a patent application and/or taking such measures
as the requester deems appropriate to establish and preserve its proprietary rights in the information in the manuscript or disclosure.
Investigators shall provide to Sponsor a non-exclusive license to any such manuscripts.

 

ARTICLE
9 – OWNERSHIP OF MATERIAL, DATA, AND INVENTIONS

 

 9.1 Sponsor shall solely own all right, title, and interest in and to:

 

		a.	all
                                         Study Materials, Study Drug, Study documents, Study information, Study programs, and
                                         suggestions of every kind and description provided to and/or otherwise communicated to
                                         CRO and/or Investigators in connection with the Study or this Agreement; and

 

    	 	7	 

     

    

 

		b.	all
                                         clinical data, CRFs, Study documents, and clinical specimens prepared and developed by
                                         CRO and/or any Investigator in connection with the Study or this Agreement whether in
                                         any form (collectively, the “Information”).

 

		c.	Information
                                         may be used by the owner of the IND for all required regulatory filings required by the
                                         FDA or other governmental body.

 

9.2
Information, as defined in Section 9.1(b) above, shall be provided to Sponsor upon reasonable request and may be utilized by
Sponsor in any way it deems legally appropriate, provided that, subject to Section 9.7 below, CRO and/or Investigator may
utilize the Information for their own internal, noncommercial research, educational purposes, Study Subject care, and/or
patient care purposes as well as to comply with any applicable law(s) and/or regulation(s). CRO acknowledges and agrees that
they shall not acquire any rights or licenses, expressed or implied, to Sponsor’s Study Drug or any of the
Sponsor’s Confidential Information, or any of Sponsor’s present and/or future patents, copyrights, trade secrets,
other intellectual property, or clinical data that directly result from the Study.

 

9.3
CRO acknowledges that they are conducting the Study in accordance with the applicable Protocol developed by the Sponsor,
wherein all provisions of the applicable Protocol have been developed by Sponsor and/or its agents, and that the Sponsor is
sponsoring the conduct of the Study in part, to expand the scope and value of Sponsor’s intellectual property
rights.

 

9.4
CRO understands and agrees that the underlying rights to the intellectual property that is the subject to this Agreement,
including without limitation all intellectual property rights in Sponsor’s drug candidates or products, are owned
solely by Sponsor. Neither CRO nor Investigators will acquire any rights of any kind whatsoever with respect to
Sponsor’s drug candidates or products as a result of conducting services under this Agreement. All rights to any
know-how, trade secrets, developments, discoveries, inventions, and/or improvements, whether patentable or not, conceived or
reduced to practice in the performance of work directly conducted as part of the Study (the “Intellectual
Property”) by CRO and/or Investigators and/or other personnel, either solely or jointly with employees, agents,
consultants, and/or other representatives of the Sponsor will be solely owned by Sponsor.

 

9.5
For any new Intellectual Property resulting from the conduct of the Study, the inventorship will be determined based on U.S.
patent law. CRO will promptly disclose to Sponsor any such Intellectual Property arising under this Agreement that CRO
becomes reasonably aware of during the term of this Agreement.

 

    	 	8	 

     

    

 

9.6
CRO agrees to assign and hereby does assign to Sponsor, at no additional compensation, all rights, title, and interest in and
to Intellectual Property discovered as a result of participation in the Study and will sign and deliver to Sponsor all
writings and do all such things as may be necessary or appropriate to vest in Sponsor all right, title, and interest in and
to such Intellectual Property. Sponsor may, in its sole discretion, file and prosecute in its name and at its expense, patent
applications on any patentable inventions within the Intellectual Property. Upon request of Sponsor, and at the sole expense
of Sponsor, CRO will execute and deliver any and all instruments necessary to transfer its ownership of such patent
applications to Sponsor and to enable Sponsor to file and prosecute such patent applications in any country.

 

9.7
Inventions and technologies owned by, licensed to, or otherwise under the control of either Party as of the Effective Date
shall remain the sole and exclusive properties of that Party. Sponsor shall retain all rights, title, and interest in and to
any intellectual property made by Sponsor, including its employees and agents, during the Study.

 

9.8
Except as expressly provided herein, neither Sponsor, Investigators, nor CRO grants or transfers to the other or to any other
party by operation of this Agreement, by implication, estoppel, or otherwise, any right or license to any patent, copyright,
trade secret, or other proprietary right of any party.

 

ARTICLE
10 – PUBLICITY

 

10.1
Except as provided in Article 8, the prior written permissions of CRO or Sponsor, as applicable, shall be obtained from the
other Party before each time CRO or Sponsor, as applicable, desires to mention or otherwise use the name, trademark, service
mark, trade name, symbol, and/or other identifying marks of the other Party in any form of advertising and/or publicity
material and/or in making any form of representation and/or statement in connection with the services and/or Study that could
be construed to constitute an express and/or implied endorsement by the other Party of any commercial product and/or service.
This prohibition shall not apply to documents filed with or disclosure required by governmental and/or regulatory bodies,
provided, however, the disclosing Party must provide the other Party with advance written notice of such
disclosure.

 

10.2
Sponsor agrees that its use of the name, symbols, and/or marks of CRO and/or names of CRO’s employees, agents,
contractors, and/or subcontractors shall be limited to identification of CRO as participants in the Study, provided that such
use does not imply endorsement of Sponsor or of any Sponsor product or service by CRO and/or Investigators.

 

10.3
CRO agrees that its use of the name, symbol, and/or marks of Sponsor and/or names of Sponsor’s employees, agents,
contractors, and/or subcontractors shall be limited to identification of Sponsor as participants in the Study, provided that
such use does not imply endorsement of CRO or of any CRO product or service by Sponsor or Investigators

 

    	 	9	 

     

    

 

10.4
Investigators’ name and statements pertaining to the Study Drug and performance thereof may be used by Sponsor to the
extent each such Investigator agrees to such use.

 

ARTICLE
11 – HUMAN SUBJECTS

 

11.1
The Parties agree that the applicable Protocol must be approved by the Institutional Review Board (“IRB”) at the
applicable Study Site before it becomes effective at that Study Site and/or before the Study commences at that applicable
Study Site. CRO and/or Investigators shall obtain from each of the Study Subjects written informed consent in compliance with
21 C.F.R. 50.20 through 50.27. The Parties acknowledge and agree that any modifications or revisions to the informed consent
form shall require the review and approval of the applicable IRB.

 

ARTICLE
12 – INDEMNIFICATION

 

12.1
Sponsor agrees to indemnify, defend, and hold harmless CRO and their respective employees, officers, directors, agents,
contractors, subcontractors, the Investigators, and other qualified personnel working in the performance of the Study
(collectively, “CRO Indemnitiees”) from and against any and all claims, causes of action, investigations, suits,
liability, losses, damages, and costs, including attorney fees and court costs, (each a “Claim”) that are based
on or related in any way to:

 

		a.	assertions
                                         and/or Claims of personal injury, death, and/or property damage sustained by Study Subjects
                                         in connection with participation in the Study, Study Drug, Study Materials, and/or applicable
                                         Protocol;

 

		b.	assertions
                                         and/or Claims of product or other liability, strict or otherwise, related to Study Drug
                                         and/or Study Materials;

 

		c.	assertions
                                         and/or Claims of intellectual property infringement arising out of or related to use
                                         of Study Drug, Study Materials, and/or the applicable protocol as otherwise permitted
                                         in this Agreement;

 

		d.	assertions
                                         and/or Claims of the negligence, recklessness, and/or intentional misconduct of Sponsor;
                                         and/or

 

		e.	any
                                         breach of this Agreement or violation of law by Sponsor.

 

Sponsor
will pay all such damages and costs of CRO Indemnitees, including all of their expenses and reasonable attorney fees incurred
in connection with all such Claims without regard to whether such Claims, causes of action, investigations, and/or suits are rightfully
or wrongfully brought and without regard to any determination of liability.

 

    	 	10	 

     

    

 

 12.2 Sponsor’s obligation to indemnify under this Article 12 shall not extend to:

 

		a.	a
                                         material failure to substantially adhere to the terms of the applicable Protocol, including
                                         amendments thereto, but excluding deviations from the terms of the applicable Protocol
                                         that arise out of medical necessity and/or excluding deviations from the terms of the
                                         applicable Protocol that arise out of express instruction from Sponsor and/or excluding
                                         deviations from the terms of the applicable Protocol that arise out of express consent
                                         from Sponsor;

 

		b.	a
                                         failure to comply with applicable FDA or other governmental requirements;

 

		c.	a
                                         failure to use generally accepted medical standards to administer the Study Drug and/or
                                         abide by express Study procedures according to the applicable Protocol; and/or

 

		d.	the
                                         negligence, recklessness, and/or intentional misconduct of an Investigator and/or a Study
                                         Site and/or CRO.

 

12.3
CRO agrees to indemnify, defend, and hold harmless Sponsor and their employees, officers, directors, and/or agents in
the performance of the Study (collectively, “Sponsor Indemnitiees”) from and against any claims, causes of
action, investigations, suits, liability, damage(s), and costs, including attorney fees and court costs, (each a
“Claim”) that are based on or related in any way to:

 

		a.	a
                                         failure, which becomes reasonably known to CRO and CRO fails to take reasonable steps
                                         to cure such failure, by Investigators to substantially adhere to the terms of the applicable
                                         Protocol, including amendments thereto, but excluding deviations from the terms of the
                                         applicable Protocol that arise out of medical necessity and/or excluding deviations from
                                         the terms of the applicable Protocol that arise out of express instruction from Sponsor
                                         and/or excluding deviations from the terms of the applicable Protocol that arise out
                                         of express consent from Sponsor;

 

		b.	a
                                         failure, which becomes reasonably known to CRO and CRO fails to take reasonable steps
                                         to cure such failure, by Investigators to comply with applicable FDA or other governmental
                                         requirements;

 

		c.	a
                                         failure, which becomes reasonably known to CRO and CRO fails to take reasonable steps
                                         to cure such failure, by the Investigators to use generally accepted medical standards
                                         to administer the Study Drug and/or abide by express Study procedures according to the
                                         applicable Protocol;

 

    	 	11	 

     

    

 

		d.	the
                                         negligence, recklessness, and/or intentional misconduct of CRO; and/or

 

		e.	any
                                         breach of this Agreement or violation of law by CRO.

 

CRO
will pay all such damages and costs of Sponsor Indemnitees, including all of their expenses and reasonable attorney fees incurred
in connection with all such Claims without regard to whether such Claims, causes of action, investigations, or suits are rightfully
or wrongfully brought and without regard to any determination of liability.

 

 12.4 CRO’s obligation to indemnify under this Article 12 shall not extend to:

 

		a.	assertions
                                         and/or Claims of personal injury, death, and/or property damage sustained by Study Subjects
                                         in connection with participation in the Study, Study Drug, Study Materials, and/or applicable
                                         protocol;

 

		b.	assertions
                                         and/or Claims of product or other liability, strict or otherwise, related to Study Drug
                                         and/or Study Materials;

 

		c.	assertions
                                         and/or Claims of intellectual property infringement arising out of or related to use
                                         of Study Drug, Study Materials, and/or the applicable Protocol as otherwise permitted
                                         in this Agreement;

 

		d.	assertions
                                         and/or Claims of the negligence, recklessness, and/or intentional misconduct of Sponsor;
                                         and/or

 

		e.	any
                                         breach of this Agreement or violation of law by Sponsor.

 

12.5
To the extent permitted by applicable federal laws and government regulations, CRO Indemnitiees will provide Sponsor
reasonably prompt notice of any Claim for which indemnification will be sought, will cooperate in the investigation and
defense of such claim, will permit Sponsor to direct the defense of such Claim, including selecting counsel, and will not
settle or compromise such Claim without the Sponsor’s written consent. Subject to the foregoing, each CRO Indemnitee
may participate in any such Claims at its/his/her own cost and expense. Sponsor shall not settle a Claim in any manner that
admits fault on behalf of the CRO Indemnitee or imposes injunctive relief on the CRO Indemnitee without such CRO
Indemnitee’s prior written consent.

 

    	 	12	 

     

    

 

12.6
To the extent permitted by applicable federal laws and government regulations, Sponsor will provide Sponsor
Indemnitee reasonably prompt notice of any Claim for which indemnification will be sought, will cooperate in the
investigation and defense of such Claim, will permit Sponsor Indemnitee to direct the defense of such Claim, including
selecting counsel, and will not settle or compromise such Claim without the Sponsor Indemnitee’s written consent.
Subject to the foregoing, each Sponsor Indemnitee may participate in any such Claims at its/his/her own cost and expense. CRO
shall not settle a Claim in any manner that admits fault on behalf of the Sponsor Indemnitee or imposes injunctive relief on
the Sponsor Indemnitee without such Sponsor Indemnitee’s prior written consent.

 

12.7 Subject
Injury. Sponsor agrees to assume responsibility for any adverse reaction and/or injury to Study Subjects (“Subject
Injury”), including the reasonable costs of treatment, that results from the Study Drug and/or a procedure required by
the applicable Protocol conducted during the Study. Sponsor shall not be responsible for Subject Injury that results
from:

 

		a.	a
                                         material deviation from the applicable Protocol, but excluding deviations from the terms
                                         of the applicable Protocol that arise out of medical necessity and/or excluding deviations
                                         from the terms of the applicable Protocol that arise out of express instruction and/or
                                         consent from Sponsor;

 

		b.	the
                                         material negligence, recklessness, and/or intentional misconduct in the performance of
                                         the Study; and/or

 

		c.	a
                                         pre-existing medical condition, an underlying disease of the Study Subject, and/or treatment
                                         that would have been provided to the Study Subject in the ordinary course of care notwithstanding
                                         participation in the Study, unless and to the extent such injury or illness was exacerbated
                                         by the use of the Study Drug or through non-ordinary course of care procedures required
                                         in accordance with the applicable Protocol.

 

12.8
Nothing in this Article 12 shall be construed as limiting any indemnification obligations under any other clause in this
Article 12. CRO agrees that it will, to the best of its ability, ensure Study sites will not seek or accept reimbursement
from any insurance or other third party for express costs paid by Sponsor.

 

12.9
The obligations of this Article 12 shall survive termination and/or suspension of this Agreement.

 

ARTICLE
13 – INSURANCE

 

13.1
Each Party shall maintain, at its own expense, an insurance policy and/or an appropriate and adequate program of
self-insurance at levels sufficient to support its obligations assumed under this Agreement and the applicable
protocol.

 

13.3
Upon written request, either Party will provide evidence of its insurance policy or self-insurance program reasonably
acceptable to the other Party. Either Party will provide the other Party with written notice of material change in its
coverage, which would affect such Party’s ability to meet its obligations under this Agreement and/or the applicable
protocol. A Party’s inability to meet its insurance obligation constitutes material breach of this
Agreement.

 

    	 	13	 

     

    

 

13.3
All of the insurance required by this Article 13 shall be carried with insurance carriers with a Best’s Financial
Strength Rating of A-VII or higher and shall be primary as respects each Party’s own responsibilities under this
Agreement. The limits of any insurance coverage required herein shall not limit the Parties’ liability under Article 12
of this Agreement.

 

ARTICLE
14 – TERM AND TERMINATION

 

14.1
This Agreement commences on the Effective Date and shall continue until the delivery of the final study report, unless
terminated earlier as provided herein.

 

14.2
The Study and this Agreement may be terminated, by written notice, by CRO for material breach of Study obligation(s) and/or
this Agreement by Sponsor, which remains uncured thirty (30) days after Sponsor’s receipt of notice of breach.
Immediately upon receipt of a notice of termination, Investigators shall stop enrolling Study Subjects into the Study and
shall cease conducting Protocol-related procedures on Study Subjects already enrolled in the Study, to the extent medically
permissible and appropriate. The termination of this Agreement shall not affect the right of CRO to receive any and all
compensation earned pursuant to this Agreement prior to the effective date of termination.

 

14.3
The Study and this Agreement may be terminated, by written notice, by Sponsor for material breach Study obligation(s) and/or
this Agreement by CRO, which remains uncured thirty (30) days after CRO’s receipt of notice of breach. It is the
Sponsor’s decision as to whether to continue Study enrollment with the Investigators.

 

14.4
Following termination of this Agreement, CRO will provide to Sponsor, upon written request by Sponsor, an accounting of all
Study Subjects, Study Drug(s), Study Materials, Study data, Confidential Information, and CRFs that are part of the
Study.

 

14.5
Notwithstanding the foregoing, in the event the FDA, for any reason, suspends the Study, Sponsor shall have the right to
suspend this Agreement immediately upon written notice to CRO. If this Agreement is suspended, each of the Parties shall
fulfill all of their respective obligations, which occur prior to the effective date of such suspension. If requested by
Sponsor, CRO and Investigators shall immediately return to Sponsor all Study Drug(s), Study Materials, Confidential
Information, and other materials and information provided by Sponsor or developed by CRO during the Study. The suspension of
this Agreement shall not affect the right of either Party to seek damages or other relief that it may be entitled to for acts
or omissions occurring prior to any suspension. The suspension of this Agreement shall not affect the right of CRO to receive
any compensation earned pursuant to this Agreement prior to the effective date of suspension or reasonably incurred to
suspend the Study. Each of the Parties agrees, upon written notice, to cooperate in good faith with the other to resume the
Study and the responsibilities of each Party under this Agreement, if and when, the suspension ceases and the Study
recommences.

 

    	 	14	 

     

    

 

14.7
Termination of this Agreement by either Party shall not affect the rights and obligations of the Parties accrued prior to the
effective date of termination. The provisions of Articles 2, 6, 7, 8, 9, 10, 12, 13, 15, and 16 shall survive the termination
or expiration of this Agreement for any reason.

 

ARTICLE
15 – FORCE MAJEURE

 

15.1
The performance by either Party of any covenant or obligation on its part to be performed hereunder is excused by floods,
strikes or other labor disturbances, riots, fires, accidents, wars, acts of terrorism, embargoes, delays of carriers,
inability to obtain materials, failure of power or natural resources to supply, acts of government, legal injunctions,
governmental restraints, including the FDA or other agencies, or any other act of God or other force majeure preventing such
performance whether similar or dissimilar to the foregoing that is beyond the reasonable control of the Party bound by such
covenant or obligation, provided, however, that the Party affected will use all reasonable endeavors to eliminate or cure or
overcome any such causes and to resume performance of its obligations with all reasonably possible speed.

 

ARTICLE
16 – MISCELLANEOUS

 

16.1
Any alteration in or amendment to this Agreement, including its attachments and Exhibits, must be in writing and signed by
both Parties prior to such alteration or amendment becoming effective. Any amendments, revisions, and/or alterations to the
applicable protocol must also be approved by the applicable IRB(s). If any amendment, revision, and/or alteration to the
applicable protocol, the scope of this Agreement as contemplated herein, and/or the scope of the Study as contemplated herein
affects the cost and/or expenses and/or the scope of the Study, the Parties shall negotiate in good faith a corresponding
change in the Budget, which shall take the form of a Change Order. Such revisions contemplated in this Article 16.1 include,
but are not limited to, Protocol amendments, requests for additional Study sites, and alterations to the identified list of
Study sites as contemplated in the Budget.

 

16.2
All notices or other communications that are required or permitted hereunder shall be in writing and delivered personally,
sent by facsimile, sent by electronic mail, sent by nationally-recognized overnight courier, or sent by registered or
certified mail, postage prepaid, return receipt requested, to each of the Parties as they reasonably request. Any such
communication shall be deemed to have been given when delivered.

 

16.3
This Agreement shall be governed by and construed in accordance with the laws of the State of Texas without reference to its
conflict of law principles. Venue for any disputes shall be fixed in Bexar County, Texas. All claims and disputes arising
under or relating to this Agreement are to be settled by binding arbitration. An award of arbitration may be confirmed in a
court of competent jurisdiction.

 

    	 	15	 

     

    

 

16.4
No waiver, amendment, and/or modification of any of the terms of this Agreement shall be valid unless in writing and signed
by authorized representatives of both parties. Failure to enforce any rights under this Agreement shall not be construed as a
waiver of such rights. No waiver of any term, provision, or condition of this Agreement, whether by conduct or otherwise, in
any one or more instances, shall be deemed to be construed as a further or continuing waiver of any such term, provision, or
condition, or of any other term, provision, or condition of this Agreement.

 

16.5
This Agreement, together with its referenced Exhibits and attachments, contains the entire Agreement of the Parties with
respect to the subject matter hereof, and supersedes all previous and contemporaneous agreements and understandings, whether
oral or written, between the Parties.

 

16.6
If any provision(s) of this Agreement should be illegal or unenforceable in any respect, the legality and enforceability of
the remaining provisions of this Agreement shall not be affected.

 

IN
WITNESS WHEREOF, the Parties have executed this Agreement as of the dates set forth below.

 

	Cancer
    Insight, LLC	 	BriaCell
    Therapeutics Corp.
	 	 	 	 	 
	DocuSigned by:	 	DocuSigned by:
		 	
	 	                                             	 	 	                                                  
	Name:	Steven
    White	 	Name:	Willam
    V. Williams
	Title:	COO	 	Title:	President
    and CEO
	Date:	9/28/2017	 	Date:	9/29/2017

 

    	 	16	 

     

    

 

EXHIBIT
A – PROTOCOL

 

The
applicable protocol, as identified above, is hereby attached and is hereby incorporated as Exhibit A, including any subsequent
amendments thereto.

 

    	 	17	 

     

    

 

EXHIBIT
B – BUDGET FOR PROTOCOL

 

The
Detailed Budget is available upon request.

 

Budget
Overview:

 

Based
on the Detailed Budget, the total cost of Cancer Insight’s services for this Study is $902,785.12, which includes the necessary
work to be performed by Cancer Insight for twenty-four (24) months of anticipated project time, three (3) Study sites activated
to the Study, and up to twenty-four (24) patients enrolled to the Study. This amount does not include the costs associated with
Study sites for Study-related activity and does not include the costs of certain vendors, which all shall be determined at a later
date and payable by Sponsor.

 

This
Study budget as provided for herein is based on certain details as discussed and communicated by both Parties, which are identified
and described in the detailed budget. If, at any point during the course of the Study and the life of this Agreement, the costs
and/or expenses and/or scope of the Study exceed the amounts as contemplated herein, CRO shall submit, in writing, a Change Order(s)
to Sponsor and each will negotiate such Change Order(s) in good faith.

 

Payment
Schedule:

 

Payment
shall be made from Sponsor to Cancer Insight based on an installment- based payment structure. CRO shall be paid $112,848.14
(the “Installment Payment”) per fiscal quarter for a total of eight (8) fiscal quarters. The first Installment
Payment shall be due on October 1, 2017. Each Installment Payment thereafter shall be due on the first day of each fiscal
quarter that follows.

 

Invoices
received by Cancer Insight from Study sites for Study-related activity shall be passed through to Sponsor as received by Cancer
Insight. Sponsor shall make such payment to Cancer Insight within fifteen (15) days of receipt. Certain vendor-related invoices
shall also be passed through directly to Sponsor as received by Cancer Insight. Sponsor shall make such payment to Cancer Insight
within fifteen (15) days of receipt.

 

Invoices
may be sent via mail or electronic mail to the appropriate parties. A late fee of 1.5% per month will be assessed for any portion
of a month after thirty (30) days of the payment due date.

 

    	 	18

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]